Mycophenolate mofetil in systemic vasculitis

Lupus

Volumn 14, Issue SUPPL. 1, 2005, Pages

  D'Cruz, David P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Mycophenolate mofetil; Systemic vasculitis; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BLADDER CANCER; BONE MARROW TOXICITY; COLITIS; CONNECTIVE TISSUE DISEASE; FEVER; HUMAN; INFERTILITY; MYALGIA; PRIORITY JOURNAL; SYSTEMIC VASCULITIS;

EID: 16244369432     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2120oa     Document Type: Article

References (15)

1. Walton EW. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2: 265-270.
2. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498.
3. Stillwell TJ, Benson RC Jr, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31: 465-470.
4. Jayne D, Rasmussen N, Andrassy K et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
5. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836-1840.
6. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-1971.
7. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-283.
8. Waiser J, Budde K, Braasch E, Neumayer HH. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis 1999; 34: e9.
9. Neumann I, Haidinger M, Jager H et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003; 14: 721-727.
10. Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002; 57: 421-424.
11. Woywodt A, Choi M, Schneider W, Kettritz R, Gobel U. Cytomegalovirus colitis during mycophenolate mofetil therapy for Wegener's granulomatosis. Am J Nephrol 2000; 20: 468-472.
12. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999; 130: 422-426.
13. Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet's disease. Dermatology 2001; 203: 322-324.
14. Assaf C, Mewis G, Orfanos CE, Geilen CC. Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. Br J Dermatol 2004; 150: 598-600.
15. Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 2000; 143: 1324.